No, you do not have to stay on GLP-1 medication forever. No rule fixes the length: under the GetLean GLP-1 Taper Plan, Dr Quek sets it at monthly reviews, with a taper toward the lowest effective dose and, where clinically appropriate, off the medication. After the STEP 1 extension's overnight stop, about two-thirds of the lost weight returned within a year (Wilding 2022); individual results vary.
The length follows the goal, the response and the plan for coming off, with the taper working towards the lowest effective dose and, where clinically appropriate, off the medication. The longest continuous exposure published is about four years, in SELECT, a cardiovascular trial of 17,604 adults (Ryan 2024). Adults who stepped down to a lower dose of tirzepatide in SURMOUNT-MAINTAIN were still 16.6% below their starting weight a year later (Horn 2026). Individual results vary.
In Singapore, tirzepatide is registered as Mounjaro, and semaglutide injection as Wegovy for weight management and as Ozempic for type 2 diabetes. The figures in this article are given by molecule, as the trials and product labels report them.
Weight plateau: the point at which weight loss slows to near-flat. The only formal definition used in this literature is a change of less than 5% over a 12-week interval, and over every 12-week interval after it.
Do you have to take Mounjaro or Wegovy forever?
No. In the trials the weight came back when the medication was taken away, by stopping it or by switching people to placebo. A planned exit is built around that. The habits that hold the result start while the medication is still working, and Dr Quek steps the dose down at the monthly reviews.
People come off for many reasons, and wanting not to depend on a weekly injection indefinitely is a legitimate one.
Is there a set length?
No. The length follows the goal, the response and the plan for coming off, not a number of months.
The lengths quoted from the trials are trial schedules rather than recommended courses: STEP 1 ran to week 68, SURMOUNT-1 to week 72, STEP 5 to week 104 and SELECT to week 208, and everyone in each treatment arm received the same length of treatment. At GetLean the length follows the plan instead. The weight comes off at a planned pace; the habits that hold it are built with daily WhatsApp coaching while the medication is quieting appetite; and the dose is then stepped down at Dr Quek's monthly reviews rather than stopped overnight.
How long have people actually been treated?
About four years is the longest continuous exposure published, and it comes from a trial that was not a weight-loss trial.
SELECT randomised 17,604 adults and its prespecified weight analysis reports that weight loss "continued over 65 weeks and was sustained for up to 4 years", reaching a mean reduction of 10.2% at week 208 against 1.5% on placebo, alongside a 7.7 cm reduction in waist circumference (Ryan 2024).
The population matters more than the number. Everyone enrolled was aged 45 or over, had a BMI of 27 or above, and had established cardiovascular disease — a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. Type 1 and type 2 diabetes were both exclusions. Mean age was 61.6 years, 72.3% were men, and mean baseline BMI was 33.3 (Ryan 2024). This is a secondary-prevention cardiovascular trial rather than a weight-management one, and its 10.2% is materially smaller than what the weight-management trials report. It should not be read as what a weight-management patient would expect.
One further precision. "Four years" is the scheduled endpoint, not everyone's exposure: mean follow-up was 39.8 months and mean treatment exposure 34.2 months (Lincoff 2023). We go through what that trial was designed to measure in long-term effects of GLP-1.
The longest run in a weight-management population is half that. STEP 5 followed 304 adults with obesity, or overweight with a weight-related comorbidity, and without diabetes, for two years: mean weight change of −15.2% at week 104 against −2.6% on placebo (Garvey 2022). It is a small trial and 93% of participants were white, so it is not a Singapore-representative population.
When does the weight stop falling?
Later than most people assume, and the answer is drug-specific.
For semaglutide, the description comes from individual trial narratives rather than a formal analysis. STEP 5's authors write that weight showed a "substantial initial reduction… which plateaued after approximately week 60 and was maintained for the remainder of the study", and the trial's own anchor points bear that out: −15.6% at week 52 and −15.2% at week 104 (Garvey 2022). SELECT's full text describes the trajectory as continuing to week 65 and then being sustained through week 208 (Ryan 2024). Both are descriptive wordings from the authors — "approximately", "appeared to" — not a statistical time-to-plateau, and the two trials do not use the same definition.
For tirzepatide there is a dedicated analysis. A post-hoc study of SURMOUNT-1 and SURMOUNT-4 defined plateau as a weight change of less than 5% over a 12-week interval and over all subsequent 12-week intervals, and found median times to plateau of 24.3, 26.0, 36.1 and 36.1 weeks across the overweight, class I, class II and class III BMI categories. By week 72, between 87.6% and 90.2% of participants had plateaued — later, on average, for those on higher doses, younger participants and women (Horn 2025). Three caveats travel with those numbers: the analysis includes only participants who were adherent and who reached at least 5% weight loss, so it describes responders; seven of the ten authors are employees and shareholders of the manufacturer and the other three report consulting or advisory income from it; and there is no equivalent published analysis for semaglutide, so the tirzepatide medians and the semaglutide narratives are not interchangeable.
When weight stopped falling in each trial this section cites; the semaglutide rows are the authors' descriptions, and the tirzepatide row is a formal analysis of responders.
| Trial | Who was in it | When weight stopped falling | Source |
|---|---|---|---|
| STEP 5 (semaglutide) | 304 adults with obesity, or overweight with a weight-related comorbidity, without diabetes | "Plateaued after approximately week 60"; −15.6% at week 52 and −15.2% at week 104 | Garvey 2022 |
| SELECT (semaglutide) | Adults aged 45 or over with a BMI of 27 or above and established cardiovascular disease, without diabetes | Continued to week 65, then sustained through week 208 | Ryan 2024 |
| SURMOUNT-1 and SURMOUNT-4, post-hoc analysis (tirzepatide) | Only participants who were adherent and reached at least 5% weight loss | Median 24.3, 26.0, 36.1 and 36.1 weeks across the overweight, class I, class II and class III BMI categories; 87.6% to 90.2% had plateaued by week 72 | Horn 2025 |
In Singapore tirzepatide's current registrations carry both a type 2 diabetes and a weight-management indication, while the 2023 injection registration SIN16718P carries type 2 diabetes only (Singapore NDF). Everything above is reported as a trial result rather than as an outcome to expect.
What does a plateau mean for the taper?
It is the point to plan the taper with the doctor, not a signal to stop on one's own.
A plateau marks the point where weight stops falling. It does not mark the point where the medicine stops acting. In STEP 5, weight flattened around week 60 and the reduced weight was then held for another full year while treatment continued (Garvey 2022). In SELECT, the curve flattened at week 65 and the reduction was held for three more years on treatment (Ryan 2024).
That makes the plateau the natural point to plan how the dose comes down. The withdrawal trials took the medication away, by stopping it or by switching people to placebo: in the STEP 1 extension, the medication and the lifestyle support stopped on the same day, with no taper, and about two-thirds of the lost weight returned within a year (Wilding 2022). Stepping down is a different picture: in SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026).
At GetLean, a plateau is the point to plan the taper with Dr Quek at the monthly review. Dose changes are made at that check-in and the decision is his, with the aim of the lowest effective dose. We favour a gradual reduction rather than a cliff-edge stop, which allows appetite to adjust incrementally while the habits take over. How much weight comes back after stopping covers what happens after an overnight stop.
Where does the two-year figure come from?
England's NHS, and it is a funding decision rather than a clinical one.
NICE Technology Appraisal TA875 recommends semaglutide for weight management "only if: it is used for a maximum of 2 years, and within a specialist weight management service", alongside BMI criteria and a suggestion to "consider stopping semaglutide if less than 5% of the initial weight has been lost after 6 months of treatment" (NICE 2023).
NICE is a health-technology assessment body, not a medicines regulator. The cap reflects the trial evidence available at the time and cost-effectiveness modelling for NHS funding; the appraisal does not claim that two years is the medically correct length of treatment. It carries no legal or clinical standing in Singapore.
The two NICE appraisals also disagree with each other. TA1026, covering tirzepatide, contains no maximum-duration sentence anywhere in its recommendations, using instead a review at six months on the highest tolerated dose if less than 5% of initial weight has been lost (NICE 2024). The appraisals were published nearly two years apart under different commercial arrangements. A figure that changes between two appraisals of the same drug class is a funding parameter, not a finding about the medicine.
Does diabetes change the numbers?
Substantially — which is why trial figures should never be lined up beside each other without stating who was in each one.
Semaglutide 2.4 mg at 68 weeks produced a mean weight change of −14.9% in adults without diabetes (Wilding 2021) and −9.6% in adults with type 2 diabetes (Davies 2021). Tirzepatide 15 mg at 72 weeks produced −20.9% in adults without diabetes (Jastreboff 2022) and −14.7% in adults with type 2 diabetes (Garvey 2023). The gap is large enough that a figure quoted without its population is close to meaningless.
Every duration and plateau dataset in this article — SELECT, STEP 5, the SURMOUNT plateau analysis — comes from a population without diabetes. None of them describes what someone with type 2 diabetes should expect on any of these questions. GetLean is a weight-management service; anyone with diabetes has that condition managed by their own doctor, and the duration question belongs in that conversation.
So what actually decides duration?
The goal, the response and the plan for coming off, reviewed month by month rather than fixed in advance.
In routine US practice, treatment often ends early. Among 125,474 US adults starting one of these medicines, 64.8% of those without type 2 diabetes had stopped within a year, against 46.5% of those with type 2 diabetes. Larger weight loss on treatment predicted lower discontinuation; moderate or severe gastrointestinal side effects predicted higher (Rodriguez 2025). That is an observational electronic-health-record study in a US insurance and access context that does not transfer to Singapore.
At GetLean, treatment duration is reviewed at the monthly check-in with Dr Quek. That check-in is the standing prompt for the conversation, and a patient can raise it at any check-in rather than wait to be asked; whether to continue, adjust or stop is his clinical decision at that review.
At GetLean, the programme is designed to end: our philosophy is that GLP-1 medication should act as a catalyst — not something to depend on indefinitely. So the length is decided by the goal, the response and the doctor's judgement, and the work that holds the result after the exit starts long before the dose comes down: the habits are built with daily WhatsApp coaching while the medication is working, and the taper is planned from the first consultation.
Individual results vary, and clinical-trial figures describe the populations studied. Never stop or change a prescribed medication on your own; how long to stay on it is a decision to make with the doctor who prescribed it.
What happens after the taper at GetLean?
Finishing the taper does not have to end the support. After the taper, a patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time: a restart begins with a review consultation, and whether to restart the medication is his decision at that review.
Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.
Common questions
How long should you stay on GLP-1 medication?
Long enough to reach the goal at a planned pace and build the habits that hold it, then a planned taper. No rule fixes a number of months. At GetLean the length is set at Dr Quek's monthly reviews, based on the goal, the response and the whole medical picture, and the dose is stepped down gradually rather than stopped overnight.
Do you have to take Mounjaro or Wegovy forever?
No. In the trials the weight came back when the medication was taken away, by stopping it or by switching people to placebo. Stepping down is a different picture: in SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026); individual results vary. At GetLean the exit is planned from the first consultation, and Dr Quek steps the dose down at the monthly reviews.
When does weight loss plateau on GLP-1 medication?
Later than most people expect, and the figures differ by drug. STEP 5's authors describe semaglutide weight loss as plateauing after approximately week 60 (Garvey 2022), and SELECT's weight analysis describes loss continuing to about week 65 (Ryan 2024). In a formal analysis for tirzepatide, median time to plateau ran from about 24 to 36 weeks depending on starting BMI class (Horn 2025). Individual results vary.
Does hitting a plateau mean the medication has stopped working?
No. The plateau marks the point where weight stops falling, not the point where the medicine stops acting. In STEP 5 the reduced weight was then held for another year on treatment (Garvey 2022), and in SELECT for three more years (Ryan 2024). At GetLean a plateau is the point to plan the taper with Dr Quek, not a signal to stop on one's own.
Is there a two-year limit on GLP-1 medication?
Not as a clinical rule. The two-year figure comes from England's NHS funding guidance, which recommends semaglutide for weight management only if it is used for a maximum of two years within a specialist service (NICE TA875). That is a health-technology funding decision rather than a safety or efficacy finding, and it has no standing in Singapore. The later tirzepatide appraisal sets no maximum duration at all (NICE TA1026).
What is the longest anyone has been treated in a trial?
About four years, in SELECT — where weight loss continued to about week 65 and was then sustained to a mean −10.2% at week 208 (Ryan 2024). That trial enrolled adults with established cardiovascular disease and overweight or obesity without diabetes, so it is not a weight-management population and its figures should not be read as one.
Can you go back on it after stopping?
Many people do. In a US study of 125,474 adults, about 65% of those without type 2 diabetes stopped within a year, and about 36% of those who stopped had restarted within the following year (Rodriguez 2025). At GetLean, a restart begins with a review consultation with Dr Quek, and whether to restart the medication is his decision.
What happens after the taper at GetLean?
A patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time; a restart begins with a review consultation, and whether to restart the medication is his decision.